Esophageal cancer Medical Services in China

Esophageal cancer is a malignant neoplasm arising from the epithelial lining of the esophagus—the muscular tube connecting the pharynx to the stomach. It is broadly classified into two histological subtypes: esophageal squamous cell carcinoma (ESCC), predominant in the upper and middle thirds and strongly associated with smoking, heavy alcohol use, and dietary carcinogens (e.g., nitrosamines, thermal injury from hot beverages); and esophageal adenocarcinoma (EAC), which arises predominantly in the distal esophagus and is closely linked to chronic gastroesophageal reflux disease (GERD) and Barrett’s esophagus—a metaplastic change where normal squamous epithelium is replaced by columnar epithelium. Pathogenesis involves progressive accumulation of genetic alterations (e.g., TP53 mutations, CDKN2A inactivation, ERBB2 amplifications) driven by chronic inflammation, oxidative stress, and impaired DNA repair mechanisms. Globally, esophageal cancer ranks sixth in incidence and fifth in cancer-related mortality, with over 600,000 new cases and 540,000 deaths annually (GLOBOCAN 2022). Incidence varies markedly by region: ESCC dominates in the 'Asian Esophageal Cancer Belt'—stretching from northern Iran through Central Asia to northern China—where rates exceed 15–30 per 100,000 person-years; EAC is more common in Western countries, particularly among white males in North America and Northern Europe. Key modifiable risk factors include tobacco smoking (2–5× increased risk), excessive alcohol consumption (especially when combined with smoking), poor nutrition (low intake of fruits/vegetables, micronutrient deficiencies), obesity (for EAC), and habitual consumption of very hot beverages (>65°C). Non-modifiable risks include male sex (3–4× higher incidence), age (>55 years), achalasia, tylosis, and prior head/neck cancers. Early-stage disease is often asymptomatic; dysphagia (initially for solids, progressing to liquids), unintentional weight loss, odynophagia, and retrosternal pain are hallmark late symptoms—leading to frequent diagnosis at advanced stages. This significantly impairs quality of life: patients experience malnutrition, dehydration, social withdrawal due to eating difficulties, anxiety about prognosis, and reduced functional independence. Palliative interventions—including stent placement or feeding tube insertion—may alleviate symptoms but do not reverse systemic decline. Psychosocial burden is high, with elevated rates of depression and caregiver strain. Multidisciplinary management involving gastroenterologists, oncologists, thoracic surgeons, radiation oncologists, and nutritionists is essential to optimize survival and preserve dignity throughout the disease trajectory.

Esophageal cancer is a malignant neoplasm arising from the epithelial lining of the esophagus, with squamous cell carcinoma (ESCC) predominant in the upper and middle thirds—especially in high-incidence regions such as northern China—and adenocarcinoma (EAC) more common in the distal esophagus and gastroesophageal junction, often associated with chronic gastroesophageal reflux disease (GERD) and Barrett’s esophagus. Accurate staging via endoscopic ultrasound (EUS), contrast-enhanced CT, PET-CT, and sometimes bronchoscopy or laparoscopy is essential to guide therapeutic decisions. Treatment strategies are highly stage-dependent and must be individualized based on tumor histology, location, extent (T/N/M status), patient performance status, comorbidities, and patient preference.

Conservative (non-surgical) management is indicated for patients with unresectable locally advanced disease, metastatic disease, or those unfit for surgery due to significant cardiopulmonary compromise or frailty. Definitive chemoradiotherapy (dCRT) remains the standard of care for medically inoperable, localized ESCC (Stage II–III), typically comprising concurrent cisplatin-based chemotherapy (e.g., cisplatin 75 mg/m² IV day 1 + 5-fluorouracil 1000 mg/m²/day IV continuous infusion days 1–4 and 29–32) with radical radiotherapy (50–50.4 Gy in 25–28 fractions). For EAC, dCRT is less established but may be considered in select cases; neoadjuvant therapy followed by surgery remains preferred when feasible. Palliative radiotherapy (30–40 Gy in 10–15 fractions) effectively alleviates dysphagia, bleeding, or pain in advanced disease. Endoscopic palliation—including argon plasma coagulation (APC), Nd:YAG laser ablation, photodynamic therapy (PDT), or self-expanding metal stents (SEMS)—provides rapid symptomatic relief for malignant obstruction, particularly in patients with short life expectancy or contraindications to systemic therapy.

Pharmacologic interventions encompass both cytotoxic and targeted agents. Platinum-fluoropyrimidine doublets (e.g., cisplatin/5-FU or oxaliplatin/capecitabine) form the backbone of first-line systemic therapy for metastatic or recurrent disease. Immunotherapy has revolutionized treatment: pembrolizumab is FDA- and NMPA-approved as first-line therapy for PD-L1–positive (CPS ≥10) unresectable or metastatic ESCC, either as monotherapy or combined with platinum-based chemotherapy. Nivolumab plus ipilimumab or nivolumab plus chemotherapy are also approved options. For HER2-positive EAC (≈15–20% of cases), trastuzumab combined with chemotherapy improves overall survival. Emerging agents include Claudin 18.2-targeted therapies (e.g., zolbetuximab) in clinical trials for gastric/esophagogastric junction adenocarcinoma. Supportive medications—including proton pump inhibitors (e.g., esomeprazole 40 mg daily) for GERD control, antiemetics (e.g., palonosetron + aprepitant), nutritional supplements (e.g., oral peptide-based formulas), and opioid analgesics for refractory pain—are integral to comprehensive care.

Surgical resection remains the only potentially curative modality for resectable esophageal cancer (Stage I–III). The procedure of choice is esophagectomy, most commonly performed via Ivor Lewis (transthoracic) or McKeown (three-incision) approaches for mid/distal tumors, or transhiatal esophagectomy for cervical/upper thoracic lesions. Minimally invasive esophagectomy (MIE), including robotic-assisted techniques, is increasingly adopted in specialized centers, offering reduced blood loss, shorter hospital stays, and lower pulmonary complication rates without compromising oncologic outcomes. Lymphadenectomy is critical: two-field (mediastinal + abdominal) dissection is standard for ESCC; three-field (adding cervical nodes) may be considered for proximal tumors. Reconstruction utilizes gastric pull-up (most common), colonic interposition, or jejunal interposition depending on anatomy and prior surgery. Neoadjuvant therapy—either chemoradiation (for ESCC) or chemotherapy alone (for EAC per CROSS and FLOT4-AIO trials)—is strongly recommended for clinically staged cT1b–cT4a, N0–N+ disease, significantly improving R0 resection rates and long-term survival.

China offers distinct advantages in esophageal cancer management. First, China hosts the world’s largest cohort of ESCC patients, fostering unparalleled clinical expertise and high-volume surgical centers—such as Peking University Cancer Hospital and Fudan University Shanghai Cancer Center—where surgeons perform >200 esophagectomies annually, correlating with superior perioperative outcomes. Second, China’s National Medical Products Administration (NMPA) has accelerated approval pathways for novel immunotherapies; pembrolizumab, camrelizumab, and tislelizumab are all approved for ESCC within months of global data release. Third, integrated traditional Chinese medicine (TCM) is routinely incorporated—not as alternative therapy but as adjunctive supportive care—to mitigate chemotherapy-induced myelosuppression (e.g., Jia Wei Xiao Yao San), improve appetite (e.g., Shen Ling Bai Zhu San), and reduce radiation esophagitis (e.g., Yin Qiao San modifications), supported by randomized trials published in journals like *Chinese Journal of Cancer Research*. Fourth, China’s centralized health information systems enable longitudinal follow-up and real-world evidence generation, informing national guidelines updated biannually by the Chinese Society of Clinical Oncology (CSCO).

Post-treatment recovery requires multidisciplinary coordination. Patients should undergo structured swallowing rehabilitation with speech-language pathologists starting preoperatively and continuing for ≥6 weeks post-esophagectomy to prevent strictures and aspiration. Nutritional support is paramount: small, frequent, soft-textured meals; avoidance of bolus foods and carbonated beverages; supplementation with vitamin B12, iron, calcium, and fat-soluble vitamins (A/D/E/K) due to malabsorption risk. Regular surveillance includes upper endoscopy every 6–12 months for the first 3 years (to detect metachronous lesions or anastomotic recurrence), annual chest/abdominal CT, and serum tumor markers (SCC for ESCC; CEA/CA19-9 for EAC). Psychosocial support—including smoking cessation counseling (mandatory, given strong synergism with alcohol and tobacco), depression screening (PHQ-9), and peer-led survivorship groups—is embedded in national quality-of-care standards. Long-term survivors must be counseled on late effects: dumping syndrome (managed with dietary modification and acarbose), bile reflux (treated with bile acid sequestrants), and increased risk of second primary cancers (especially head/neck and gastric), warranting lifelong endoscopic surveillance. Adherence to evidence-based follow-up protocols correlates with 5-year overall survival exceeding 65% in Stage II and 45% in Stage III disease at leading Chinese centers.